The ROS1ders Announces Recipients of 2024 ROS1+ Cancer Innovation Awards
Astro Bug/10314070
Trending...
- Advanced Solar Space Technology; Record Efficiency of 15.7%; Agreement to Provide NOVI Space with Rollable PV Array Blankets for Space Launch in 2026
- Behavioral Health Advocates to Hold Joint Capitol Hill Press Conference on June 11
- DealMagik Successfully Concludes National Floral Design Contest with Over 150 Submissions
SACRAMENTO, Calif. - AstroBug -- The ROS1ders, a global group of patients and caregivers living with ROS1+ cancer, announced the recipients of the 2024 ROS1+ Cancer Innovation Award. Funds for the awards were raised through individual contributions to The ROS1ders by patients and supporters. Each award carries a one-year, $75,000 seed grant to fund high-risk, high-reward research projects in ROS1+ cancer.
The recipients of the 2024 ROS1+ Cancer Innovation Awards are:
More on Astro Bug
About The ROS1ders
The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 2000 people from over 50 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaborations with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
About ROS1+ Cancer
More on Astro Bug
The recipients of the 2024 ROS1+ Cancer Innovation Awards are:
- Monte Winslow, PhD, Dmitri A. Petrov, PhD and Joel Neal, MD, PhD, Stanford University School of Medicine – Towards precision medicine for oncogenic ROS1 fusion driven lung cancer
This project will create models of each known ROS1 fusion variant and investigate how they influence cancer development and treatment responses. - Jaime Schneider, MD, PhD, Massachusetts General Hospital – Identifying Metabolic Vulnerabilities in ROS1+ Lung Cancer
This project aims to shed light on metabolic pathways that may contribute to acquired resistance to treatments for ROS1+ cancer, with the goal of identifying new targets for treatments that may prevent or treat resistance mechanisms.
More on Astro Bug
- DivX Enhances AVI Playback Resources; Simplifies Guide to Playing AVI Files with DivX Software
- Patrick Aloni Joins Historic Gold and Copper Discovery in Argentina with Multimillion-Dollar Stake
- Edtech Startup Young Commanders Launches 'Visionaries Without Sight' Collection Celebrating Blind and Visually Impaired Historical Figures
- Goldstar Rehabilitation Celebrates 15 Years of Early Intervention Across Southeastern PA
- United States Congressional Candidate Peter Coe Verbica Unveils 25-Point Federal Plan to Help Make California Affordable Again
About The ROS1ders
The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 2000 people from over 50 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaborations with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
About ROS1+ Cancer
- ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer. The incidence is thought to be similar in other types of cancer.
- Biomarker testing for ROS1 fusions is recommended in guidelines for non-small cell lung cancer, but few other cancers, yet.
- Patients typically have adenocarcinoma NSCLC, a younger age than the average NSCLC patient, and no smoking history (a smoking history should not exclude patients from biomarker testing or targeted therapies).
- Oral targeted therapies are the recommended first-line treatment for metastatic ROS1+ NSCLC and have increased the survival of patients by years. However, these drugs eventually stop working due to acquired resistance. The mechanisms of resistance are not well understood.
More on Astro Bug
- D8Averse Launches D8Acapture: Disruptive Mobile-First App Transforms Utility Pole Data Collection
- Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
- Mauro Schnaidman named as Managing Director in Miami, Florida
- Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
- Anern Shines at SOLAR AFRICA Kenya with Solar Lithium Battery Storage Technology
Source: The ROS1ders, Inc.
0 Comments
Latest on Astro Bug
- csky.ai & DuoKey Launch Secure AI Transcription Solution for Microsoft 365
- PlayClay.io Launches Streamlined Quoting Platform for Manufacturers' Reps and Distributors
- Let's Talk Series: At the Crossroads: Immigration Today
- Cyta Cyprus Selects Axiros' AXESS Platform for Cloud-Native, Data-Driven Device Management
- DealMagik Successfully Concludes National Floral Design Contest with Over 150 Submissions
- Behavioral Health Advocates to Hold Joint Capitol Hill Press Conference on June 11
- VNBTC Becomes The Top Crypto Investment Platform As Its Bitcoin Cloud Mining Solution Goes Viral
- Advanced Solar Space Technology; Record Efficiency of 15.7%; Agreement to Provide NOVI Space with Rollable PV Array Blankets for Space Launch in 2026
- Urgent Reform Demanded to Stop Child Abuse in Youth Behavioral Facilities
- Cyrus O'Leary's Mini Cream Pies - The Latest Dessert Innovation from Sara Lee Frozen Bakery Delivers Indulgence in Single-Servings
- Emerge Apps Launches Mod Performance Suite: A New Era of Work Comp Selling for Insurance Agents
- Imagine waking up every day knowing you can earn $, and actually making it happen. Are you ready to change your life? Let's get started!
- ETH Price Prophecy: Is $3,000 Within Reach? — HASHJ Best Cloud Mining Platform Focuses on Gas-Optimized Mining
- Mental Health Watchdog Calls Baker Acting of Children in Florida a Parental Rights Violation
- Injured While Using Rideshare?
- Wealthywet's Miami Swim Week 2025 Debut Signals a New Era of Luxury in Swimwear
- Luxury Waterfront Home in Porto Sol Community Now Available Through Innovative "Name Your Price" Approach
- BREAKING CONSUMER ALERT: Carvana's "Certified" Luxury SUV Buyer Exposes Legal & Mechanical Trauma 'Presses' Charges of Duress, Deception, and Delay
- JMC Princess Announces Release of Empowering New Single "PRETTY" – A Summer Anthem for Young Girls Everywhere
- $3.9M Q1 2025 Revenue Following $39M in Cybersecurity Contracts for Education and Transportation Sectors: Cycurion, Inc